ClearPoint Neuro Inc vs Vanguard Value Index Fund ETF — how do they compare? ClearPoint Neuro Inc trades at $15.97 (market cap $478.63M), while Vanguard Value Index Fund ETF trades at $218.38. The key difference: Vanguard Value Index Fund ETF is trading nearer its 52-week high, ClearPoint Neuro Inc nearer its low. Which is the better fit depends on your goals.
| CLPT | VTV | |
|---|---|---|
Market Cap | $478.63M | — |
Sector | Health | — |
52-Week High | $29.60 | $220.51 |
52-Week Low | $8.66 | $175.51 |
Enterprise Value | $506.63M | — |
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
VTV trades at $219.36, up 0.07% with a bullish technical outlook supported by moving averages and near-term resistance at $220. The ETF benefits from investor rotation into value stocks amid AI sector volatility, offering diversification with low tech exposure and a recent dividend declaration. It has gained 16% year-to-date, reflecting strong momentum in large-cap value equities.
The outlook remains positive as value stocks attract flows away from stretched growth valuations, though Fed policy and inflation risks could pressure returns. VTV's low expense ratio and defensive tilt provide stability, but macroeconomic shifts pose headwinds for continued outperformance.
Trailing returns across standard periods
Latest headlines on both assets
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →